Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice.

• Publication year

  2016

• Venue

  International Journal of Molecular Sciences

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms17091580PMID 27657044PMCID 5037845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AR‐V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate

  2017cited by this paper
• Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.

  2017cited by this paper
• Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.

  2016cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients with Metastatic Castration‑Resistant Prostate Cancer

  2016cited by this paper
• Prognosis of Castration-resistant Prostate Cancer Patients - Use of the AdnaTest® System for Detection of Circulating Tumor Cells.

  2016cited by this paper
• Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

  2016cited by this paper
• Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer.

  2015cited by this paper
• Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

  2015cited by this paper
• Detecting predictive androgen receptor modifications in circulating prostate cancer cells

  2015cited by this paper
• Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.

  2015cited by this paper
• Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

  2015cited by this paper
• Docetaxel and Prednisone with or without Lenalidomide in Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer ( MAINSAIL ) : A Randomised , Double-Blind , Placebo-Controlled Phase 3 Trial

  2015cited by this paper
• A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer

  2015cited by this paper
• Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

  2015cited by this paper
• Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.

  2015cited by this paper
• Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

  2015cited by this paper
• RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance

  2015cited by this paper
• Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

  2015cited by this paper
• Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells

  2015cited by this paper
• Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis

  2014cited by this paper
• Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score.

  2014cited by this paper
• AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

  2014cited by this paper
• Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in baseline and progressive metastatic castration resistant prostate cancer (mCRPC).

  2014cited by this paper
• Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells

  2014cited by this paper
• The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.

  2014cited by this paper
• Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

  2014cited by this paper
• Tumor self-seeding by circulating tumor cells in nude mouse models of human osteosarcoma and a preliminary study of its mechanisms

  2014cited by this paper
• Estrogen Rapidly Enhances Incisional Pain of Ovariectomized Rats Primarily through the G Protein-Coupled Estrogen Receptor

  2014cited by this paper
• Organoid cultures derived from patients with advanced prostate cancer.

  2014cited by this paper
• Method validation of circulating tumour cell enumeration at low cell counts

  2013cited by this paper
• High‐Purity Prostate Circulating Tumor Cell Isolation by a Polymer Nanofiber‐Embedded Microchip for Whole Exome Sequencing

  2013cited by this paper
• Epithelial–mesenchymal transition markers expressed in circulating tumor cells in hepatocellular carcinoma patients with different stages of disease

  2013cited by this paper
• Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients

  2013cited by this paper
• Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting

  2013cited by this paper
• NanoVelcro Chip for CTC enumeration in prostate cancer patients.

  2013cited by this paper
• Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers.

  2013cited by this paper
• Cancer statistics, 2013

  2013cited by this paper
• Biomarkers in prostate cancer surveillance and screening: past, present, and future

  2013cited by this paper
• Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

  2013influential reference
• Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer.

  2013cited by this paper
• mRNA-Seq of Single Prostate Cancer Circulating Tumor Cells Reveals Recapitulation of Gene Expression and Pathways Found in Prostate Cancer

  2012cited by this paper
• Publication of tumor marker research results: the necessity for complete and transparent reporting.

  2012cited by this paper
• Circulating tumor cells in prostate cancer: a potential surrogate marker of survival.

  2012cited by this paper
• Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

  2012cited by this paper
• EAU guidelines on prostate cancer . Part I : screening , diagnosis , and treatment of clinically localised disease

  2012cited by this paper
• A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire

  2012cited by this paper
• ApoStream(™), a new dielectrophoretic device for antibody independent isolation and recovery of viable cancer cells from blood.

  2012cited by this paper
• Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic Device

  2012cited by this paper
• The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer.

  2012cited by this paper
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  2012cited by this paper
• The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy

  2011cited by this paper
• Angiogenesis , Metastasis , and the Cellular Microenvironment Circulating Tumor Cells from Patients with Advanced Prostate and Breast Cancer Display Both Epithelial and Mesenchymal Markers

  2011cited by this paper
• Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.

  2011cited by this paper
• A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas

  2011cited by this paper
• Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

  2011cited by this paper
• EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

  2011cited by this paper
• 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood

  2011cited by this paper
• Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients

  2011cited by this paper
• External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study

  2011cited by this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cited by this paper
• High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system.

  2011cited by this paper
• AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

  2010cited by this paper
• Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.

  2010cited by this paper
• Portable Filter-Based Microdevice for Detection and Characterization of Circulating Tumor Cells

  2010cited by this paper
• Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents

  2010cited by this paper
• All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer.

  2010cited by this paper
• Circulating tumor cells and sample size: the more, the better.

  2010cited by this paper
• Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data.

  2009influential reference
• Circulating tumor cells are transcriptionally similar to the primary tumor in a murine prostate model.

  2009cited by this paper
• The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group

  2009cited by this paper
• Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

  2009cited by this paper
• Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer.

  2009cited by this paper
• Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer

  2009cited by this paper
• Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.

  2009cited by this paper
• Circulating tumor cells in solid tumor in metastatic and localized stages.

  2009cited by this paper
• Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer

  2009cited by this paper
• Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

  2008cited by this paper
• Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor.

  2008cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

  2008cited by this paper
• Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

  2007cited by this paper
• Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

  2007cited by this paper
• Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.

  2007cited by this paper
• Circulating tumor cells (CTC) detection: clinical impact and future directions.

  2007influential reference
• Isolation of rare circulating tumour cells in cancer patients by microchip technology

  2007cited by this paper
• Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

  2007cited by this paper
• Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.

  2005cited by this paper
• Circulating tumor cells predict survival in patients with metastatic prostate cancer.

  2005cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004cited by this paper
• Apoptosis of circulating tumor cells in prostate cancer patients

  2004cited by this paper
• Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer

  2004cited by this paper
• RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy.

  2003cited by this paper
• Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood.

  2002cited by this paper
• Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells.

  2000cited by this paper
• Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone.

  1999cited by this paper
• [Detection of circulating epithelial cells in prostate cancer].

  1997cited by this paper
• Cancer statistics

  1989cited by this paper

• Usefulness of Liquid Biopsy for Intraocular Malignancies

  2022cites this paper
• Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives

  2020cites this paper
• Profiling Circulating Tumour Cells for Clinical Applications Profiling Circulating Tumour Cells for Clinical Applications

  2019influential citation
• A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens

  2019cites this paper
• Circulating Tumor Cells as Surrogate Biomarker for Overall Survival in Metastatic Prostate Cancer

  2019cites this paper
• Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients

  2019cites this paper
• Circulating tumor cells in patients with lung cancer: developments and applications for precision medicine.

  2019cites this paper
• Chemopreventive role of arabinogalactan against experimentally induced pulmonary carcinogenesis: a study in relation to its initiation phase

  2019cites this paper
• The Significance of Circulating Tumour Cells in the Clinic

  2019cites this paper
• Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer.

  2019cites this paper
• Profiling Circulating Tumour Cells for Clinical Applications

  2018influential citation
• Clinical Utility of Circulating Tumor Cells – A Clinician’s Current View

  2017influential citation
• Integrating Genomics into Drug Discovery and Development: Challenges and Aspirations

  2017cites this paper
• Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer

  2017cites this paper
• Evaluation of theranostic nanocarriers for near-infrared imaging and photodynamic therapy on human prostate cancer cells.

  2017cites this paper